Akebia Therapeutics AKBA
NASDAQ AKBA
$0.87 +0.00 (+0.00%)
At close: Oct 2, 2026 · 4:00 PM EDT

Akebia Therapeutics (AKBA) Cost of Revenue (2019 - 2026)

Updated

Akebia Therapeutics (AKBA) recorded Cost of Revenue of $10.42 million in Q2 2026, up 5.1% from $9.92 million a year earlier but down 15.2% from the prior quarter.

Analysis

Akebia Therapeutics (AKBA) Cost of Revenue (2019 - 2026) Analysis & Trends

On a TTM basis, Akebia Therapeutics' Cost of Revenue came in at $44.63 million as of Jun 30, 2026, down 14.3% year-over-year; for FY2025, it was $39.46 million, down 37.5% from FY2024.

  • Annual Cost of Revenue has declined for five straight years, with a five-year compound annual growth rate of -33.2% (FY2020 to FY2025).
  • Across earlier years, Cost of Revenue came in at $63.18 million in FY2024 (-14.8%), $74.15 million in FY2023 (-13.3%), $85.57 million in FY2022 (-43.2%) and $150.67 million in FY2021 (-49.2%).
  • Quarterly Cost of Revenue has ranged from -$3.43 million in Q4 2022 to $47.63 million in Q4 2021 over the past five years.
  • On a year-over-year basis, Cost of Revenue rose in three of the last eight quarters, with an average decline of 11.8%.
  • Peak year-over-year performance for Cost of Revenue in the last five years was growth of 140.1% in Q3 2022, against a decline of 64.6% in Q2 2022 at the low end.
  • Per Business Quant, the preceding three quarters came in at $12.29 million (Q1 2026), $12.54 million (Q4 2025) and $9.38 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cost of Rev (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 3.27 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 8.05 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 4.29 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn 4.40 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 3.71 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 2.52 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 2.81 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn 1.58 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 4.09 Bn
10 Akebia Therapeutics 236.42 Mn -433.06 Mn 38.70 Mn 10.42 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 10.42 Mn
Mar 31, 2026 12.29 Mn
Dec 31, 2025 12.54 Mn
Sep 30, 2025 9.38 Mn
Jun 30, 2025 9.92 Mn
Mar 31, 2025 7.63 Mn
Dec 31, 2024 20.37 Mn
Sep 30, 2024 14.16 Mn
Jun 30, 2024 17.05 Mn
Mar 31, 2024 11.61 Mn
Dec 31, 2023 18.67 Mn
Sep 30, 2023 18.01 Mn
Jun 30, 2023 17.28 Mn
Mar 31, 2023 20.19 Mn
Dec 31, 2022 -3.43 Mn
Sep 30, 2022 38.28 Mn
Jun 30, 2022 18.60 Mn
Mar 31, 2022 23.11 Mn
Dec 31, 2021 47.63 Mn
Sep 30, 2021 15.94 Mn
API Access

Akebia Therapeutics Cost of Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cost-of-revenue&ticker=AKBA&period=max&api_key=YOUR_API_KEY